Hence, we speculate that PFKFB4 plays a prominent role in tumour cell stemness transformation and acquired CDK4/6 inhibitor resistance and targeting PFKFB4 might be an ideal strategy for ER+ BC chemotherapy. The gene discussed is CDK4; the disease is breast cancer.